FY2026
Effective from
- Specificity changed
- Code-level rules changed
Lipodystrophy, not elsewhere classified
Category — select a more specific code
CDC/NCHS · FY2026Whipple's disease (K90.81)
codes for associated conditions
histiocytosis X (chronic) (C96.6)
Ehlers-Danlos syndromes (Q79.6-)
For US diagnosis claims covered by HIPAA, ICD-10-CM is required from October 1, 2015.
Use the service date for outpatient/professional claims and the discharge date for hospital inpatient claims. Earlier encounters use ICD-9-CM; each individual code must also be valid for the applicable date.
Official coding guidelines → · CMS ↗First observed · 2015-10-01
Latest recorded change · FY2026
Effective from
Lipodystrophy, not elsewhere classified
Category — select a more specific code
CDC/NCHS · FY2026| All editions | Effective from | Code history |
|---|---|---|
| FY2016 | 2015-10-01 | First observed |
| FY2017 | 2016-10-01 | No tabular change |
| FY2018 | 2017-10-01 | No tabular change |
| FY2019 | 2018-10-01 | No tabular change |
| FY2020 | 2019-10-01 | Inherited rules changed |
| FY2020 · April | 2020-04-01 | No tabular change |
| FY2021 | 2020-10-01 | Inherited rules changed |
| FY2021 · 01-01 | 2021-01-01 | No tabular change |
| FY2022 | 2021-10-01 | Inherited rules changed |
| FY2022 · 04-01 | 2022-04-01 | No tabular change |
| FY2023 | 2022-10-01 | No tabular change |
| FY2023 · 04-01 | 2023-04-01 | No tabular change |
| FY2024 | 2023-10-01 | Inherited rules changed |
| FY2024 · 04-01 | 2024-04-01 | No tabular change |
| FY2025 | 2024-10-01 | No tabular change |
| FY2025 · 04-01 | 2025-04-01 | No tabular change |
| FY2026 | 2025-10-01 | Specificity changed · Code-level rules changed |
| FY2026 · April | 2026-04-01 | No tabular change |
| FY2027 | 2026-10-01 | No tabular change |
Historical mapping only; not an automatic code substitution.
Whipple's disease (K90.81)
histiocytosis X (chronic) (C96.6)
codes for associated conditions
All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.
Ehlers-Danlos syndromes (Q79.6-)
E88.10Lipodystrophy, unspecifiedBillable / specificE88.11Partial lipodystrophyBillable / specificE88.12Generalized lipodystrophyBillable / specificE88.13Localized lipodystrophyBillable / specificE88.14HIV-associated lipodystrophyBillable / specificE88.19Other lipodystrophy, not elsewhere classifiedBillable / specificOther entries in the same category; these are not automatic substitutes.
| Code | Description | Category · further specificity required |
|---|---|---|
| E88.0 | Disorders of plasma-protein metabolism, not elsewhere classified | Category · further specificity required |
| E88.2 | Lipomatosis, not elsewhere classified | Billable / specific |
| E88.3 | Tumor lysis syndrome | Billable / specific |
| E88.4 | Mitochondrial metabolism disorders | Category · further specificity required |
| E88.8 | Other specified metabolic disorders | Category · further specificity required |
| E88.9 | Metabolic disorder, unspecified | Billable / specific |
| E88.A | Wasting disease (syndrome) due to underlying condition | Billable / specific |
Official titles and instructions are preserved in their source language. Official sources ↗